Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide.
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Chiasma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHMA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CHMA underperformed the US Pharmaceuticals industry which returned 5.6% over the past year.
Return vs Market: CHMA underperformed the US Market which returned 5.3% over the past year.
Price Volatility Vs. Market
How volatile is Chiasma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StCompanies Like Chiasma (NASDAQ:CHMA) Are In A Position To Invest In Growth
4 months ago | Simply Wall StHow Much Are Chiasma, Inc. (NASDAQ:CHMA) Insiders Spending On Buying Shares?
5 months ago | Simply Wall StDoes Chiasma, Inc. (NASDAQ:CHMA) Have A Particularly Volatile Share Price?
Is Chiasma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CHMA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CHMA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CHMA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: CHMA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHMA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHMA is good value based on its PB Ratio (2.5x) compared to the US Pharmaceuticals industry average (3.2x).
How is Chiasma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: CHMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CHMA's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if CHMA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CHMA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHMA's Return on Equity is forecast to be high in 3 years time
How has Chiasma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHMA is currently unprofitable.
Growing Profit Margin: CHMA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CHMA is unprofitable, but has reduced losses over the past 5 years at a rate of 1.6% per year.
Accelerating Growth: Unable to compare CHMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: CHMA has a negative Return on Equity (-59.87%), as it is currently unprofitable.
How is Chiasma's financial position?
Financial Position Analysis
Short Term Liabilities: CHMA's short term assets ($84.1M) exceed its short term liabilities ($13.4M).
Long Term Liabilities: CHMA's short term assets ($84.1M) exceed its long term liabilities ($1.6M).
Debt to Equity History and Analysis
Debt Level: CHMA's debt to equity ratio (0.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CHMA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CHMA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CHMA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Chiasma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CHMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CHMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHMA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHMA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raj Kannan (56yo)
Mr. Raj Kannan has been Chief Executive Officer and Director at Kiniksa Pharmaceuticals, Ltd. since June 2019. Mr. Kannan has over 25 years of pharma industry experience. He has held a variety of roles fro ...
CEO Compensation Analysis
Compensation vs Market: Raj's total compensation ($USD6.41M) is above average for companies of similar size in the US market ($USD1.36M).
Compensation vs Earnings: Insufficient data to compare Raj's compensation with company performance.
|CEO & Director||1.08yrs||US$6.41m||0.013% $29.5k|
|VP & General Counsel||0.83yr||US$499.52k||no data|
|Senior Vice President of Clinical Development & Medical Affairs||3.5yrs||US$730.93k||0.022% $49.1k|
|Vice President of Finance & Administration||3.67yrs||US$362.35k||no data|
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|Executive VP & Chief Commercial Officer||0.25yr||US$1.57m||no data|
|Vice President of Marketing||0.83yr||no data||no data|
|Executive Director of Human Resources||0.92yr||no data||no data|
|Head of Clinical||4.33yrs||no data||no data|
Experienced Management: CHMA's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|CEO & Director||1.08yrs||US$6.41m||0.013% $29.5k|
|Independent Director||12.17yrs||US$122.13k||no data|
|Independent Director||4.67yrs||US$128.13k||no data|
|Independent Director||12.75yrs||US$149.63k||0.27% $622.8k|
|Independent Chairman||5.67yrs||US$151.13k||no data|
|Independent Director||5.42yrs||US$130.63k||0.11% $255.1k|
|Independent Director||16.5yrs||US$113.13k||no data|
Experienced Board: CHMA's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.4%.
Chiasma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Chiasma, Inc.
- Ticker: CHMA
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$227.824m
- Shares outstanding: 54.77m
- Website: https://www.chiasma.com
Number of Employees
- Chiasma, Inc.
- Building C East
- 140 Kendrick Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHMA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2015|
|CXS||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2015|
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/15 00:13|
|End of Day Share Price||2020/07/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.